These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 23409749)

  • 1. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
    Capitanio U; Salonia A; Briganti A; Montorsi F
    Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.
    Villa L; Capogrosso P; Capitanio U; Martini A; Briganti A; Salonia A; Montorsi F
    Adv Ther; 2019 Jan; 36(1):1-18. PubMed ID: 30523608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Jung JH; Kim J; MacDonald R; Reddy B; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012615. PubMed ID: 29161773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
    Fonseca J; Martins da Silva C
    Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Profile of silodosin].
    Montorsi F
    Urologiia; 2013; (2):112-4, 116-7. PubMed ID: 23789376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
    Wu YJ; Dong Q; Liu LR; Wei Q
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
    Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.